Comparing Approaches to Migraine Management: Evidence, Options, and Clinical Trade-offs

How migraine management is organized

Comparing approaches to migraine management begins with two distinct objectives: treating an established attack and reducing the likelihood, severity, or disability of future attacks. Primary care guidance describes a structured process called RATE: Recognize, Assess, Treat, and Evaluate. The approach is intended for settings where access to neurologists or headache specialists may be limited, and it emphasizes diagnosis, symptom history, physical and neurologic examination, evidence-based treatment, and continuing review. 2

Acute treatment is generally assessed by pain relief, freedom from pain, associated symptom control, and persistence of benefit. Preventive treatment is assessed over a longer period using outcomes such as migraine frequency, severity, functional impairment, tolerability, and adherence. This distinction matters because a medicine that works during an attack may not be appropriate for prevention, while preventive therapies require sustained evaluation rather than a single-dose response. 3

Acute medicines: NSAIDs, triptans, and newer options

A comparative review of adult outpatient studies identified 21 head-to-head studies and 165 placebo-controlled studies of acute migraine treatment. Triptans were the most effective category for pain relief at two hours and freedom from pain for as long as 48 hours. When an NSAID or acetaminophen is insufficient, adding a triptan can provide substantial symptom relief for many patients, although adverse effects occur somewhat more often than with some alternatives. 3

The same evidence found that combining a triptan with an NSAID was more effective than using the triptan alone, while adding acetaminophen to a triptan did not improve pain relief. The analysis reported no clear advantage for newer ditan and gepant classes in the comparisons examined, and it did not include older options such as metoclopramide, ergotamine, or prochlorperazine. Treatment selection therefore depends on response, contraindications, associated symptoms, and prior treatment experience. 3

Triptans and gepants: different clinical trade-offs

Triptans act as selective 5-HT1B/1D receptor agonists and are described in the supplied review as rapid-onset acute therapies. Their vasoconstrictive effects can limit use in people with cardiovascular disease. Gepants target the CGRP pathway without vasoconstriction, which may make them an alternative for some patients who cannot use triptans, although the review characterizes their onset as slower. Neither category is universally preferable because safety and effectiveness depend on individual clinical circumstances. 6

CGRP-targeted treatment has also expanded beyond acute care into prevention. The Lancet Neurology commentary identifies a major evidence gap caused by the limited number of rigorous head-to-head trials comparing CGRP therapies with established, lower-cost oral preventives. This gap is important because conventional therapies remain an initial step in many health systems, even when migraine-specific treatments are available. Comparative decisions must therefore account for evidence quality, access, tolerability, and treatment persistence. 1

Preventive medication: established therapies versus CGRP targeting

Traditional preventive medicines include beta-blockers, antiepileptics, antidepressants, and calcium channel blockers. A comparative review describes their long-standing use alongside limitations involving efficacy, tolerability, and adherence. CGRP monoclonal antibodies and small-molecule gepants represent a more migraine-specific approach, with reported evidence suggesting reductions in monthly migraine days and a favorable adverse-effect profile in comparison with some conventional therapies. Cost, access, and long-term safety remain important limitations. 7

Recent head-to-head research has directly examined newer preventive agents against topiramate. The Lancet Neurology report cites an erenumab versus topiramate randomized, double-blind, active-controlled phase 4 trial and identifies a newer atogepant versus topiramate phase 3b trial. These comparisons are more informative than placebo-only studies because they place newer therapies against medicines already used in routine care, while still requiring careful interpretation of trial populations and endpoints. 1

Non-pharmacological and behavioral approaches

Non-drug management includes yoga, acupuncture, exercise, manual therapy, biofeedback, and cognitive behavioral therapy. A targeted mini-review reported that the studies it examined consistently showed reductions in migraine frequency, severity, and disruption of daily life. It associated yoga with autonomic stability, acupuncture with lasting relief from headache days, and exercise and manual therapy with reduced muscle tension. The review also emphasized that these interventions are relevant when medication is poorly tolerated or insufficient. 4

Behavioral approaches are not necessarily substitutes for medication, and their practical value often depends on sustained participation and individualized planning. Lifestyle measures commonly discussed in migraine care include consistent sleep, hydration, and identification of personal triggers. Neuromodulation devices, including external trigeminal nerve stimulation, provide another non-drug category. These options broaden management beyond pharmacology, but the available evidence varies by intervention, study design, patient group, and measured outcome. 4

Chronic migraine, supplements, and treatment monitoring

Botulinum toxin type A is identified in the supplied research as an approved preventive option specifically for chronic migraine, defined as 15 or more headache days per month. This distinguishes it from approaches used for episodic migraine and illustrates why headache frequency is central to treatment selection. Monitoring should consider headache days, attack intensity, acute medicine use, disability, adverse effects, and whether the treatment remains acceptable over time. 2

Magnesium, riboflavin, and coenzyme Q10 are frequently used as supplemental preventive strategies and are generally characterized in the supplied background information as having favorable safety profiles. However, “natural” does not mean risk-free, and supplements can still require attention to dose, interactions, medical conditions, and product quality. A preprint Bayesian network meta-analysis comparing CGRP monoclonal antibodies with oral gepants is explicitly labeled not peer-reviewed, so its findings should not guide clinical practice independently. 8

How to interpret evidence and choose an approach

Comparisons should begin with the migraine pattern, including attack frequency, duration, associated symptoms, disability, cardiovascular history, previous treatment response, and potential medication overuse. Acute medicines are judged by speed and durability of relief, whereas preventives are judged by sustained reduction in migraine burden and acceptable tolerability. Primary care frameworks recommend repeated evaluation rather than a one-time decision, particularly when diagnosis, treatment response, or neurologic findings remain uncertain. 2

No single approach resolves every clinical problem. Triptans have extensive acute-treatment experience but may be unsuitable for some cardiovascular patients; gepants avoid vasoconstriction but may have a slower onset. Conventional preventives may be familiar and widely incorporated into health systems, while CGRP therapies offer migraine-specific targeting but face access and long-term evidence questions. A balanced plan therefore weighs effectiveness, safety, monitoring demands, patient preferences, and the quality of comparative evidence. 5

Sources

1. The Lancet Neurology
2. The Journal for Nurse Practitioners
3. American Academy of Family Physicians
4. PubMed Central
5. Journal of Education, Health and Sport: Pharmacological Management of Acute Migraine
6. Journal of Education, Health and Sport: Advances in Acute Migraine Therapy
7. Annals of Neurology and Neuroscience
8. medRxiv